alemtuzumab + tacrolimus

Alemtuzumab (Campath-1H) plus tacrolimus is a combination immunosuppressive regimen primarily used in the context of kidney (renal) transplantation. Alemtuzumab is a humanized monoclonal antibody targeting CD52 on lymphocytes, leading to profound and prolonged lymphocyte depletion. Tacrolimus is a calcineurin inhibitor that suppresses T-cell activation by inhibiting interleukin-2 transcription. This combination has been studied as an induction and maintenance protocol to prevent organ rejection while minimizing the need for additional immunosuppressants such as steroids or mycophenolate mofetil. Clinical trials have shown that this regimen can be at least as effective as traditional triple-drug regimens in preventing acute rejection episodes and maintaining graft function, with similar safety profiles but potentially higher rates of certain infections such as cytomegalovirus[1][2][3].

Brand names

Campath

Other names

alemtuzumab + tacrolimusCampath-1H + tacrolimus